Edwards Lifesciences Corporation $EW Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 2,124.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 641,869 shares of the medical research company’s stock after purchasing an additional 613,017 shares during the period. Allspring Global Investments Holdings LLC owned 0.11% of Edwards Lifesciences worth $54,771,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $266,000. Westerkirk Capital Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter valued at about $493,000. Beacon Pointe Advisors LLC raised its stake in Edwards Lifesciences by 3.4% in the 2nd quarter. Beacon Pointe Advisors LLC now owns 30,359 shares of the medical research company’s stock valued at $2,374,000 after purchasing an additional 995 shares during the last quarter. Groupe la Francaise lifted its holdings in Edwards Lifesciences by 719.4% in the 2nd quarter. Groupe la Francaise now owns 19,174 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 16,834 shares in the last quarter. Finally, PharVision Advisers LLC acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $209,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $81.46 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The firm has a market capitalization of $46.97 billion, a price-to-earnings ratio of 44.52, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a 50 day moving average price of $81.78 and a 200 day moving average price of $81.72.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. This trade represents a 24.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,827,387.38. This represents a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 61,718 shares of company stock worth $5,236,281 over the last three months. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EW. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. JPMorgan Chase & Co. raised shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.96.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.